250 related articles for article (PubMed ID: 29908878)
1. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
Wilczak W; Wittmer C; Clauditz T; Minner S; Steurer S; Büscheck F; Krech T; Lennartz M; Harms L; Leleu D; Ahrens M; Ingwerth S; Günther CT; Koop C; Simon R; Jacobsen F; Tsourlakis MC; Chirico V; Höflmayer D; Vettorazzi E; Haese A; Steuber T; Salomon G; Michl U; Budäus L; Tilki D; Thederan I; Fraune C; Göbel C; Henrich MC; Juhnke M; Möller K; Bawahab AA; Uhlig R; Adam M; Weidemann S; Beyer B; Huland H; Graefen M; Sauter G; Schlomm T
Eur Urol; 2018 Sep; 74(3):376-386. PubMed ID: 29908878
[TBL] [Abstract][Full Text] [Related]
2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
3. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
[TBL] [Abstract][Full Text] [Related]
5. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
[TBL] [Abstract][Full Text] [Related]
6. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
[TBL] [Abstract][Full Text] [Related]
7. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
[TBL] [Abstract][Full Text] [Related]
8. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Shiota M; Takamatsu D; Matsui Y; Yokomizo A; Morizane S; Saito R; Miyake M; Tsutsumi M; Yamamoto Y; Tashiro K; Tomida R; Narita S; Edamura K; Yamaguchi T; Hashimoto K; Kato M; Kasahara T; Yoshino T; Akamatsu S; Kaneko T; Matsukawa A; Matsumoto R; Joraku A; Saito T; Kato T; Kato M; Enokida H; Sakamoto S; Terada N; Kanno H; Nishiyama N; Kimura T; Kitamura H; Eto M;
Ann Surg Oncol; 2024 Jun; 31(6):3872-3879. PubMed ID: 38353798
[TBL] [Abstract][Full Text] [Related]
9. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
10. Predicting pelvic lymph node involvement in current-era prostate cancer.
Rahman S; Cosmatos H; Dave G; Williams S; Tome M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
[TBL] [Abstract][Full Text] [Related]
11. [Extended sentinel lymph node dissection in radical prostatectomy for prostate cancer: a study in the Kiel risk population].
Hautmann S; Beitz S; Naumann M; Lützen U; Seif C; Stübinger SH; van der Horst C; Braun PM; Leuschner I; Henze E; Jünemann KP
Urologe A; 2008 Mar; 47(3):299-303. PubMed ID: 18273596
[TBL] [Abstract][Full Text] [Related]
12. Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
Montorsi F; Gandaglia G; Fossati N; Suardi N; Pultrone C; De Groote R; Dovey Z; Umari P; Gallina A; Briganti A; Mottrie A
Eur Urol; 2017 Sep; 72(3):432-438. PubMed ID: 27600589
[TBL] [Abstract][Full Text] [Related]
13. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
14. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
15. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
Nini A; Gandaglia G; Fossati N; Suardi N; Cucchiara V; Dell'Oglio P; Cazzaniga W; Luzzago S; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
[TBL] [Abstract][Full Text] [Related]
17. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.
Tilki D; Reich O; Graser A; Hacker M; Silchinger J; Becker AJ; Khoder W; Bartenstein P; Stief CG; Loidl W; Seitz M
Eur Urol; 2013 May; 63(5):792-6. PubMed ID: 22902037
[TBL] [Abstract][Full Text] [Related]
18. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Mattevi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli MA; Migliorini F; Siracusano S; Artibani W
Urol Int; 2017; 99(4):392-399. PubMed ID: 28486228
[TBL] [Abstract][Full Text] [Related]
19. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.
Martínez-Piñeiro L; Rios E; Martínez-Gomariz M; Pastor T; de Cabo M; Picazo ML; Palacios J; Perona R
Eur Urol; 2003 Apr; 43(4):342-50. PubMed ID: 12667714
[TBL] [Abstract][Full Text] [Related]
20. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
